MMP7 and idiopathic pulmonary fibrosis: No difference in SP-A and SP-D levels in deceased IPF patients compared to survivorsPrediction of the risk of mortality by SP-A levels higher than 80.3 ng/mL with a sensitivity of 75% and a specificity of 67.1% but not an independent risk factor of mortalityThe association of high levels of MMP7 and SP-A associated with the risk of progression: 42% of patients with high levels of both biomarkers will progress (decrease of more than 10% of FVC) and only 9% of patients with low levels of both biomarkers will progress